Millions of UK Patients Unknowingly Risking Drug Poisoning Through Painkiller Combinations
Millions of British patients prescribed common pain medications could be unknowingly exposing themselves to serious drug poisoning risks, according to alarming new research from University College London. The comprehensive study reveals that combining gabapentinoid medications with other widely prescribed drugs dramatically increases the likelihood of severe adverse effects requiring hospitalisation.
Dangerous Drug Combinations Identified
Researchers discovered that patients taking gabapentinoids alongside benzodiazepines – sedative medications including diazepam and valium used for anxiety and insomnia – faced double the risk of hospitalisation for drug poisoning. Even more concerning, the combination of gabapentinoids with opioid painkillers such as codeine, tramadol and morphine was associated with a substantial 30 percent increased risk of hospital admission.
Despite these clear dangers, the study found that prescribing practices continue to place patients at risk. An astonishing 89 percent of patients involved in the research had been prescribed opioids alongside gabapentinoids, while more than half had also received benzodiazepine prescriptions during their treatment.
Rapidly Increasing Prescription Rates
Dr Kenneth Man, the study's lead author, explained the concerning trend: 'Prescription rates for gabapentinoids have been increasing rapidly in recent years, as they are seen as a safe alternative to opioids. While they can be effective for pain relief and do have better perceived safety profiles than opioids, there are still substantial risks that clinicians and patients should be mindful of.'
The scale of gabapentinoid use is staggering, with more than 4.5 million people in England prescribed these medications annually, primarily in the form of gabapentin or pregabalin. These drugs rank as the seventh most prescribed medication in the United States, while previous UCL research documented a more than fourfold increase in global usage across 65 countries between 2008 and 2018.
Comprehensive Research Methodology
To assess gabapentinoid safety comprehensively, researchers analysed UK data from 16,827 individuals prescribed these medications between 2010 and 2020. The team examined hospital admissions for drug poisoning before, during and after treatment periods while tracking all other prescribed medications.
The analysis focused on patients who experienced at least one hospitalisation for drug poisoning – representing just under two percent of those prescribed gabapentinoids during the study period. Researchers examined up to ten years of data for each individual, allowing direct comparison between periods when patients were and were not taking the medications.
Severe Symptoms and Hospitalisation Risks
Symptoms of drug poisoning can range from confusion and nausea to seizures, airway blockages and potentially fatal outcomes. Severe cases require urgent hospitalisation where medical professionals administer counteracting drugs to reverse the poisoning effects. Approximately 10,000 Britons are hospitalised annually for drug poisoning incidents.
The study identified both intentional and accidental poisoning cases involving gabapentinoids, including incidents involving medication misuse or doses exceeding prescribed amounts. Particularly alarming findings revealed that patients taking both gabapentinoids and benzodiazepines were four times more likely to be hospitalised for drug poisoning during the first four weeks after starting treatment compared to periods when they took neither medication.
Prescribing Patterns and Risk Factors
Dr Andrew Yuen, the study's first author, noted concerning prescribing patterns: 'A clinician's decision to prescribe gabapentinoids may sometimes be an attempt to minimise the risk of drug poisoning linked to opioids or other medications. While the risk of poisoning did decrease somewhat after patients began gabapentinoid treatment, they still faced an elevated risk of drug poisoning, which suggests that clinicians need to remain vigilant to the risks.'
Researchers discovered that gabapentinoids are frequently prescribed when patients already face heightened poisoning risks, such as during periods of worsening symptoms. The medications work by acting on GABA pathways in the brain to relieve pain and produce sedative effects, but long-term use can lead to physical dependence and difficult withdrawal symptoms for some patients.
Regulatory Response and Safety Warnings
These findings follow recent regulatory action by the Medicines and Healthcare products Regulatory Agency, which strengthened warnings about gabapentinoids regarding addiction, dependence, withdrawal and tolerance risks. The MHRA implemented these changes after a comprehensive safety review highlighted dangers associated with gabapentinoid painkillers, benzodiazepine tranquillisers and Z-drugs used for sleep disorders.
Patient information leaflets for treatments addressing conditions from nerve pain to sleep disorders now carry explicit warnings stating: 'May cause addiction, dependence and withdrawal reactions.' The Commission on Human Medicines supported additional changes including stronger warnings against combining these medications with opioids or alcohol and explicit instructions not to share medications with others.
Clinical Recommendations and Future Implications
Dr Kenneth Man emphasised the balanced approach needed: 'Our findings do not suggest that gabapentinoids are unsafe or should not be prescribed, but clinicians should be cautious when prescribing them, particularly if a patient is taking other medications as well, and clinicians should closely monitor patients who are taking them.'
Addiction clinics have reported increasing cases of patients turning to online sellers or street dealers after developing tolerance and requiring higher doses to achieve therapeutic effects. This concerning trend underscores the importance of careful prescribing practices and patient monitoring to prevent medication misuse and dangerous drug interactions.
The research highlights the critical need for healthcare providers to carefully evaluate medication combinations and maintain heightened awareness of potential poisoning risks when prescribing gabapentinoids alongside other common medications.
